AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a probe into alleged legal breaches tied to drug importation and data ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

British pharmaceutical giant AstraZeneca on Tuesday said it takes "very seriously" China's investigations into potential illegal data collection and drug imports by the group that led to the detention ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...